Salix Pharmaceuticals Ltd., a prominent player in the pharmaceutical industry, is headquartered in the United States and focuses primarily on gastrointestinal disorders. Founded in 2001, the company has made significant strides in developing innovative therapies that address unmet medical needs, particularly in the areas of irritable bowel syndrome and inflammatory bowel disease. Salix is renowned for its core products, including prescription medications that offer unique mechanisms of action, setting them apart in a competitive market. With a strong commitment to research and development, Salix has achieved notable milestones, solidifying its position as a leader in gastrointestinal health. The company continues to expand its operational reach, serving patients across North America and beyond, while maintaining a focus on delivering high-quality, effective treatments.
How does Salix Pharmaceuticals Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Salix Pharmaceuticals Ltd.'s score of 30 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Salix Pharmaceuticals Ltd., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the pharmaceutical industry is increasingly focusing on sustainability and reducing greenhouse gas emissions. Companies are encouraged to adopt science-based targets and engage in initiatives that promote environmental responsibility. As of now, Salix Pharmaceuticals has not disclosed any specific climate pledges or reduction initiatives.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Salix Pharmaceuticals Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.